溶瘤病毒治疗的发展：从基因修饰到联合治疗。
Development of oncolytic virotherapy: from genetic modification to combination therapy.
机构信息
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Fudan University, Shanghai, 200032, China.
Yantai Yuhuangding Hospital, Qingdao University, Yantai, 264000, China.
出版信息
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
Abstract
Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.
摘要
溶瘤病毒治疗（OVT）是一种利用天然或基因改造病毒选择性在恶性肿瘤细胞中复制并杀死肿瘤细胞的新型免疫治疗方法。目前已经开发出许多具有增强肿瘤靶向性、抗肿瘤疗效和安全性的基因改造溶瘤病毒（OV），其中一些已经在临床试验中进行了评估。将 OVT 与其他免疫疗法相结合可以显著提高抗肿瘤疗效。在这项工作中，我们回顾了野生型病毒在 OVT 中的应用和 OV 基因改造的策略。我们还回顾和讨论了 OVT 与其他免疫疗法的联合应用。
相似文献
1
Development of oncolytic virotherapy: from genetic modification to combination therapy.
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
2
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Front Immunol. 2021 Oct 5;12:721830. doi: 10.3389/fimmu.2021.721830. eCollection 2021.
3
Oncolytic viruses and their application to cancer immunotherapy.
Cancer Immunol Res. 2014 Apr;2(4):295-300. doi: 10.1158/2326-6066.CIR-14-0015.
4
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
J Transl Med. 2023 Jul 25;21(1):500. doi: 10.1186/s12967-023-04360-8.
5
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Front Immunol. 2020 Apr 28;11:683. doi: 10.3389/fimmu.2020.00683. eCollection 2020.
6
Oncolytic Virus-Driven Biotherapies from Bench to Bedside.
Small. 2023 Jun;19(23):e2206948. doi: 10.1002/smll.202206948. Epub 2023 Mar 6.
7
Genetic modification of oncolytic viruses to enhance antitumor immunity.
Methods Enzymol. 2020;635:231-250. doi: 10.1016/bs.mie.2019.05.017. Epub 2019 Jun 11.
8
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001647.
9
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17.
10
Application of oncolytic virus in tumor therapy.
J Med Virol. 2023 Apr;95(4):e28729. doi: 10.1002/jmv.28729.
引用本文的文献
1
Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis.
EClinicalMedicine. 2025 Jul 19;86:103362. doi: 10.1016/j.eclinm.2025.103362. eCollection 2025 Aug.
2
Oncolytic Viruses as a Novel Therapeutic Approach for Colorectal Cancer: Mechanisms, Current Advances, and Future Directions.
Cancers (Basel). 2025 May 31;17(11):1854. doi: 10.3390/cancers17111854.
3
Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges.
Front Cell Dev Biol. 2025 Feb 3;13:1517369. doi: 10.3389/fcell.2025.1517369. eCollection 2025.
4
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.
J Transl Med. 2024 Nov 5;22(1):1000. doi: 10.1186/s12967-024-05794-4.
5
Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges.
MedComm (2020). 2024 Oct 10;5(10):e755. doi: 10.1002/mco2.755. eCollection 2024 Oct.
6
Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape.
World J Gastrointest Oncol. 2024 Jul 15;16(7):2867-2876. doi: 10.4251/wjgo.v16.i7.2867.
7
OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
Int J Mol Sci. 2024 May 3;25(9):5007. doi: 10.3390/ijms25095007.
8
Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.
Int J Mol Sci. 2024 Feb 7;25(4):2042. doi: 10.3390/ijms25042042.
9
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting.
Cancers (Basel). 2024 Jan 9;16(2):281. doi: 10.3390/cancers16020281.
10
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
Front Immunol. 2023 Dec 15;14:1308890. doi: 10.3389/fimmu.2023.1308890. eCollection 2023.
本文引用的文献
1
Tumour-intrinsic resistance to immune checkpoint blockade.
Nat Rev Immunol. 2020 Jan;20(1):25-39. doi: 10.1038/s41577-019-0218-4. Epub 2019 Sep 30.
2
Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.
Ann Surg Oncol. 2019 Dec;26(13):4633-4641. doi: 10.1245/s10434-019-07691-3. Epub 2019 Aug 14.
3
Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
BioDrugs. 2019 Oct;33(5):485-501. doi: 10.1007/s40259-019-00367-0.
4
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
Clin Cancer Res. 2019 Oct 1;25(19):5818-5831. doi: 10.1158/1078-0432.CCR-18-4022. Epub 2019 Jul 4.
5
A review of chimeric antigen receptor T-cells in lymphoma.
Expert Rev Hematol. 2019 Jul;12(7):551-561. doi: 10.1080/17474086.2019.1629901. Epub 2019 Jun 19.
6
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
Nat Commun. 2019 May 28;10(1):2235. doi: 10.1038/s41467-019-10043-0.
7
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
Mol Ther Oncolytics. 2019 Mar 27;14:1-14. doi: 10.1016/j.omto.2019.03.005. eCollection 2019 Sep 27.
8
Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors.
Mol Ther Oncolytics. 2019 Mar 20;13:14-21. doi: 10.1016/j.omto.2019.03.001. eCollection 2019 Jun 28.
9
Poxvirus oncolytic virotherapy.
Expert Opin Biol Ther. 2019 Jun;19(6):561-573. doi: 10.1080/14712598.2019.1600669. Epub 2019 Apr 4.
10
Recombinant adenoviruses expressing apoptin suppress the growth of MCF‑7 breast cancer cells and affect cell autophagy.
Oncol Rep. 2019 May;41(5):2818-2832. doi: 10.3892/or.2019.7077. Epub 2019 Mar 18.
Zotero 插件